ArticlePLoS neglected tropical diseases2026
The cobras (genus Naja) of Myanmar: An updated species list with information on identification, distributions, and medical importance.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cobra diversity of Myanmar has long been a source of confusion, complicating public health responses to snakebites resulting from this medically important genus. By integrating distributional data, natural history information, and clinical evidence, we clarify the composition and distribution of Myanmar's cobra fauna and evaluate the implications for envenoming and snakebite management. We confirm the presence of five cobra species (Naja fuxi, N. kaouthia, N. mandalayensis, N. siamensis, and N. sumatrana) in Myanmar through voucher specimens and/or diagnostic photographic records and identify one additional unconfirmed species (N. sagittifera) that may occur in the country based on distributional proximity. Encounter records showed significant within-year temporal variation, with reports peaking in December and during the dry season. Because data derive from opportunistic citizen science submissions, these patterns likely reflect seasonal differences in detection and human activity rather than biological seasonality. Differences from wet-season peaks reported elsewhere highlight the importance of sampling framework in shaping apparent temporal trends. Review of clinical and toxicological information shows that only one species is represented in locally produced antivenom, raising concern about limited cross-neutralization for other cobra species in the country. Traditional practices remain common in many communities and include harmful methods that delay access to medical care or worsen injuries. Clinical evidence demonstrates that neurotoxicity, respiratory failure, and localized tissue destruction are the principal complications of cobra envenoming, often requiring antivenom therapy, airway support, mechanical ventilation, infection management, and surgical intervention in severe cases. The broader-than-recognized diversity of cobras in Myanmar, combined with high encounter probabilities, synanthropic tendencies, and gaps in public awareness, continues to hinder effective management of snakebite. Improved community education, expanded venom and antivenom research, and timely access to appropriate medical care are essential for reducing the burden of cobra envenomation in Myanmar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.